- Vertex Pharmaceuticals Inc.
- Auxilium Pharmaceuticals Inc.
- Warner Chilcott PLC
- Napo Pharmaceuticals Inc.
- Merck KGaA
- Merck Serono SA
- Takeda Pharmaceuticals International GmbH
- Altana AG
- Fougera Pharmaceuticals Inc.
- UCB Group
- Schwarz Pharma AG
- Gilead Sciences Inc.
- Amgen Inc.
- Genzyme Corp.
- Takeda Oncology
- Actelion Pharmaceuticals Ltd.
- Infinity Pharmaceuticals Inc.
- MedImmune LLC
- Mindray Medical International Ltd.
- Natus Medical Inc.
- Conor Medsystems LLC
- Zogenix Inc.
- Stryker Corp.
- Collagen Matrix Inc.
- Blackstone Medical Inc.
- OsteoBiologics Inc.
- Orthofix Medical Inc.
- Smith & Nephew PLC
- Smith & Nephew Endoscopy
- Covidien Ltd.
- United States Surgical
- Confluent Surgical Inc.
- Becton Dickinson & Co.
- BD Diagnostics-TriPath
- PerkinElmer Inc.
- JN Macri Technologies LLC
- NTD Laboratories Inc.
- PolyMedica Corp.
- Alere Inc.
- Vertex nets $286mm with FOPO
- Auxilium Pharmaceuticals nets $43.3mm with private financing
- Warner Chilcott completes $1bn IPO
- Napo raises £11.9mm with listing on LSE
- Merck KGAA to buy Serono for CHF16.6bn
- Nycomed is buying Altana's pharma business for €4.5bn
- UCB to buy Schwarz Pharma for €4.2bn
- Gilead acquires remaining Corus shares for $365mm
- Amgen acquires Avidia for $290mm plus $90mm earn-out
- Millennium to buy AnorMed; outbid
- Actelion, Roche to develop and market immunological treatment
- Infinity, MedImmune, AZ restructure Hedgehog deal
- Mindray Medical International nets $133.6mm in US IPO
- Natus Medical nets $29mm in FOPO
- Follow-on nets Conor Medsystems $89.9mm
- Start-up Zogenix grosses $60mm with Series A; adds $18mm
- Stryker Orthopedics sells two products for Collagen Matrix
- Orthofix acquires Blackstone Medical for $333mm in cash
- S&N buys OsteoBiologics for $72.3mm in cash
- US Surgical to buy Confluent for $245mm
- BD to buy TriPath for $350mm
- PerkinElmer buys Macri Technologies, NTD Labs for $56.65mm
- PolyMedica sells $174mm in convertible notes
- Inverness Medical nets $145.4mm with private financing
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.